David Devos,Z Ioav Cabantchik,Caroline Moreau,Véronique Danel,Laura Mahoney-Sanchez,Hind Bouchaoui,Flore Gouel,Anne-Sophie Rolland,James A Duce,Jean-Christophe Devedjian,FAIRPARK-II and FAIRALS-II studygroups,Julien Cassereau,Marie Bost,Charlotte Abrial,Jeanne Muller,Audrey Olivier,Gwendal Le Masson,Stéphane Mathis,Dieynaba Djigo,Sarah Bonabaud,Mathilde Deloire,Steeve Genestet,Elsa Menanteau,Pauline Bourgeois,Mathilde Lefilliatre,Fausto Viader,Mouloud Abrou,Damien Chavanne,Rachida Bari,Nathalie Guy,Sophia Sickout Arondo,Sandrine Rouvet,Katell Beauvais,Mathilde Aidan,Olivier Madec,Veronique Danel-Brunaud,Celine Tard,Marie Pleuvret,Valerie Santraine,Julie Moutarde,Philippe Couratier,Géraldine Lautrette,Selma Machat,Marie Penoty,Olivier Villeneuve,Clémence Labetoulle,Julie Catteau,Emilien Bernard,Juliette Svahn,Camille Neuillet,Shahram Attarian,Aude-Marie Grapperon,Annie Verschueren,Amandine Parlanti,Nacime Heddadji,William Camu,Sophie Pittion-Vouyovitch,Maud Michaud,Anne Chatelain,Isabelle Costa,Marie-Hélène Soriani,Arnaud Declemy,Carole Barre,François Salachas,Ivan Kolev,Jean-Christophe Antoine,Jean-Philippe Camdessanche,Nathalie Dimier,Karine Ferraud,Vincent Visneux,Marie-Cécile Fleury,Pascal Cintas,Blandine Acket,Magali Centelles,Véronique Hermet,Philippe Corcia,Stephane Beltran,Salah Bakkouche

Abstract:Focal iron accumulation associated with brain iron dyshomeostasis is a pathological hallmark of various neurodegenerative diseases (NDD). The application of iron-sensitive sequences in magnetic resonance imaging has provided a useful tool to identify the underlying NDD pathology. In the three major NDD, degeneration occurs in central nervous system (CNS) regions associated with memory (Alzheimer's disease, AD), automaticity (Parkinson's disease, PD) and motor function (amyotrophic lateral sclerosis, ALS), all of which require a high oxygen demand for harnessing neuronal energy. In PD, a progressive degeneration of the substantia nigra pars compacta (SNc) is associated with the appearance of siderotic foci, largely caused by increased labile iron levels resulting from an imbalance between cell iron import, storage and export. At a molecular level, α-synuclein regulates dopamine and iron transport with PD-associated mutations in this protein causing functional disruption to these processes. Equally, in ALS, an early iron accumulation is present in neurons of the cortico-spinal motor pathway before neuropathology and secondary iron accumulation in microglia. High serum ferritin is an indicator of poor prognosis in ALS and the application of iron-sensitive sequences in magnetic resonance imaging has become a useful tool in identifying pathology. The molecular pathways that cascade down from such dyshomeostasis still remain to be fully elucidated but strong inroads have been made in recent years. Far from being a simple cause or consequence, it has recently been discovered that these alterations can trigger susceptibility to an iron-dependent cell-death pathway with unique lipoperoxidation signatures called ferroptosis. In turn, this has now provided insight into some key modulators of this cell-death pathway that could be therapeutic targets for the NDD. Interestingly, iron accumulation and ferroptosis are highly sensitive to iron chelation. However, whilst chelators that strongly scavenge intracellular iron protect against oxidative neuronal damage in mammalian models and are proven to be effective in treating systemic siderosis, these compounds are not clinically suitable due to the high risk of developing iatrogenic iron depletion and ensuing anaemia. Instead, a moderate iron chelation modality that conserves systemic iron offers a novel therapeutic strategy for neuroprotection. As demonstrated with the prototype chelator deferiprone, iron can be scavenged from labile iron complexes in the brain and transferred (conservatively) either to higher affinity acceptors in cells or extracellular transferrin. Promising preclinical and clinical proof of concept trials has led to several current large randomized clinical trials that aim to demonstrate the efficacy and safety of conservative iron chelation for NDD, notably in a long-term treatment regimen.

Iron chelation by deferiprone does not rescue the Niemann-Pick Disease Type C1 mouse model

Defective iron homeostasis and hematological abnormalities in Niemann-Pick disease type C1

Characterization of the Neuroprotective Potential of Derivatives of the Iron Chelating Drug Deferiprone

Cur@SF NPs alleviate Friedreich’s ataxia in a mouse model through synergistic iron chelation and antioxidation

Mitochondrial ferritin upregulation by deferiprone reduced neuronal ferroptosis and improved neurological deficits via NDRG1/Yap pathway in a neonatal rat model of germinal matrix hemorrhage

A Novel C19ORF12 Mutation in Two MPAN Sisters Treated with Deferiprone

Efficacy of the iron‐chelating agent, deferiprone, in patients with Parkinson's disease: A systematic review and meta‐analysis

Iron status influences mitochondrial disease progression in Complex I-deficient mice

Iron chelation by oral deferoxamine treatment decreased brain iron and iron signaling proteins

Iron Chelator Deferiprone Restores Iron Homeostasis and Inhibits Retinal Neovascularization in Experimental Neovascular Age-Related Macular Degeneration

Iron Chelation Nanoparticles with Delayed Saturation As an Effective Therapy for Parkinson Disease.

New Deferric Amine Compounds Efficiently Chelate Excess Iron to Treat Iron Overload Disorders and to Prevent Ferroptosis

Multi-Copper Ferroxidase-Deficient Mice Have Increased Brain Iron Concentrations and Learning and Memory Deficits

Iron Chelator Deferasirox Rescued Mice from Fas‐induced Fulminant Hepatitis

Polymeric Nanoparticles Enhance the Ability of Deferoxamine to Deplete Hepatic and Systemic Iron

Conservative iron chelation for neurodegenerative diseases such as Parkinson's disease and amyotrophic lateral sclerosis

Differential Interferon Signaling Regulation and Oxidative Stress Responses in the Cerebral Cortex and Cerebellum Could Account for the Spatiotemporal Pattern of Neurodegeneration in Niemann–Pick Disease Type C

Clinically available iron chelators induce neuroprotection in the 6-OHDA model of Parkinson's disease after peripheral administration

Hephaestin and ceruloplasmin play distinct but interrelated roles in iron homeostasis in mouse brain.

Intranasal deferoxamine reverses iron-induced memory deficits and inhibits amyloidogenic APP processing in a transgenic mouse model of Alzheimer's disease.

Neurodegeneration in Niemann-Pick type C disease mice